This study presents a novel photothermal-immunotherapy combination strategy for bladder cancer, leveraging the synergistic activation of tumor-associated macrophages by R848 and a photothermal agent to significantly enhance anti-tumor immune responses. It offers a translational solution to overcome the low response rates associated with immune checkpoint inhibitors.
Literature Overview
The article titled 'Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy,' published in ACS Nano, systematically investigates the application of R848 and photothermal agent DTPA co-loaded lipid nanoparticles (R848/DTPA@DSPE-PEG NP) in bladder cancer immunotherapy. By constructing a photothermal-responsive nanoplatform, the study achieves synergistic effects between localized photothermal therapy (PTT) and immune stimulation, significantly activating both innate and adaptive immune responses and reshaping the immunosuppressive tumor microenvironment. This strategy not only effectively suppresses primary and distant tumor growth but also markedly extends survival, offering a new avenue for comprehensive immune intervention in bladder cancer.Background Knowledge
Bladder cancer (BCa) is one of the most common malignant tumors of the urinary system, characterized by high recurrence and metastasis risks. Although immune checkpoint blockade (ICB), such as anti–PD-1/PD-L1 antibodies, has achieved certain efficacy in advanced patients, the overall response rate remains only 10%–30%, with issues of acquired resistance. The main bottleneck lies in the highly immunosuppressive tumor immune microenvironment (TIM), marked by insufficient CD8+ T-cell infiltration, enrichment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and polarization of tumor-associated macrophages (TAMs) toward the M2 phenotype, all of which suppress anti-tumor immunity. Additionally, antigen-presenting cells (APCs) such as dendritic cells (DCs) exhibit impaired function, further weakening T-cell activation. Therefore, effectively reversing the TIM, promoting M1 macrophage polarization, and enhancing antigen presentation are key strategies to overcome current limitations in immunotherapy. This study employs R848—a TLR7/8 agonist—to target and activate innate immunity, combined with photothermal therapy (PTT) to induce immunogenic cell death (ICD), achieving dual immune activation precisely addressing these mechanistic challenges.
Research Methods and Experiments
The study utilized the MB49 cell line to establish subcutaneous and orthotopic bladder cancer models in C57BL/6J mice to evaluate the therapeutic efficacy of the nanoparticles both in vitro and in vivo. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) were used to physically characterize R848/DTPA@DSPE-PEG NPs, confirming an average particle size of approximately 212.2 nm and a zeta potential of -34.2 mV, indicating good dispersity and stability. In vitro experiments confirmed effective cellular uptake of the nanoparticles by RAW264.7 and MB49 cells using flow cytometry and confocal microscopy. Upon irradiation with a 635 nm laser, the nanoparticles exhibited excellent photothermal conversion efficiency, inducing reactive oxygen species (ROS) generation and ICD, evidenced by upregulation of CRT, HMGB1, and HSP70. Further analysis via qRT-PCR and Western blot of apoptosis-related proteins Bax, Bcl-2, Cyt C, and cleaved caspase-9 confirmed that the photothermal effect activates the mitochondrial-dependent apoptotic pathway.
To evaluate immunomodulatory functions, the study employed bone marrow–derived macrophages (BMDMs) and dendritic cells (BMDCs), using flow cytometry to detect expression of M1 markers CD86 and mature DC markers CD80, demonstrating that R848 significantly promotes M1 polarization and DC maturation. In vivo biodistribution studies using near-infrared fluorescence imaging showed significant nanoparticle accumulation at the tumor site, maintaining strong signals up to 48 hours. In both subcutaneous and orthotopic models, combined with laser irradiation, R848/DTPA@DSPE-PEG NPs significantly inhibited tumor growth, prolonged survival, enhanced CD8+ T-cell infiltration, and reduced M2 macrophages. Finally, RNA-Seq transcriptomic analysis revealed significant upregulation of immune-related genes such as IFN-γ, CXCL10, and IRF7, along with activation of TLR and TNF signaling pathways.Key Conclusions and Perspectives
Research Significance and Prospects
This study introduces a novel photothermal-immunotherapy paradigm for bladder cancer, achieving synergistic activation of innate and adaptive immunity through precise delivery of R848 combined with PTT-induced ICD. Its promotion of M1 polarization directly targets the immunosuppressive function of TAMs in the TIM, offering high specificity. The strategy not only enhances CD8+ T-cell responses but also significantly improves the tumor immune microenvironment, providing a replicable technical pathway for immune activation in 'cold' tumors.
From a drug development perspective, this nanoplatform demonstrates excellent biocompatibility and tumor targeting, making it suitable for further clinical advancement. Its light-controlled release enables high local drug concentrations, reducing systemic toxicity and improving the therapeutic index. Future studies may explore its application in other solid tumors, particularly those with low response rates to ICB.
In terms of disease modeling, this study underscores the importance of immune microenvironment reprogramming, suggesting that interactions among tumor cells, immune cells, and stromal cells must be considered when constructing immunotherapy models. Furthermore, integrating single-cell sequencing technologies could provide higher-resolution data on dynamic changes in TAMs and T-cell subsets, advancing mechanistic understanding.
Conclusion
The thermosensitive R848-loaded lipid nanoparticles developed in this study, when combined with photothermal therapy, successfully reprogrammed the bladder cancer immune microenvironment. By inducing immunogenic cell death and activating TLR7/8 signaling, this strategy effectively promotes tumor-associated macrophage polarization toward the M1 phenotype, enhances dendritic cell maturation and CD8+ T-cell infiltration, and significantly boosts anti-tumor immune responses. More importantly, its synergistic effect with anti–PD-1 antibodies markedly suppresses primary and distant tumor growth and extends survival, offering a powerful solution to overcome the low response rates of current immune checkpoint inhibitors. This study not only provides new therapeutic hope for bladder cancer patients but also offers a referenceable nanoplatform design strategy for combination immunotherapies in other solid tumors. From bench to bedside, this approach has strong translational potential and could become an integral component of future comprehensive bladder cancer treatments, driving precision immunotherapy toward greater efficacy and safety.
